Temsirolimus and Valproic Acid in Treating Young Patients With Relapsed Neuroblastoma, Bone Sarcoma, or Soft Tissue Sarcoma

Inclusion Criteria

• •DISEASE CHARACTERISTICS:
• •Histologically confirmed malignant solid tumor at original diagnosis, including the following:
• •* Neuroblastoma
• •* Bone sarcomas (primary neuroectodermal tumors/ Ewing sarcoma (PNET/ES), osteosarcoma)
• •* Soft tissue sarcomas (rhabdosarcoma and related tumors)
• •Histologically confirmed of relapsed disease is highly recommended but not mandatory
• •Measurable disease according to RECIST
• •Refractory or progressive disease after ≥ 1 and ≤ 4 prior chemotherapy regimens
• •* Patients with neuroblastoma, PNET/ES, or rhabdosarcoma must have failed a cyclophosphamide/topotecan-containing regimen
• •* Stem cell transplantation, including preparative regimen and post-transplant immunotherapy, is considered to be 1 regimen
• •PATIENT CHARACTERISTICS:
• •Karnofsky performance status (PS) 50-100% (or Lansky PS 50-100%)
• •Life expectancy ≥ 8 weeks
• •ANC ≥ 750/mm\^3
• •Platelet count ≥ 75,000/mm\^3 (transfusion independent)
• •Hemoglobin 8.0 g/dL (may receive RBC transfusions)
• •* Patients with tumor metastatic to bone marrow are allowed to receive transfusions to maintain hemoglobin and platelet counts
• •Serum creatinine normal
• •Total bilirubin ≤ 1.5 times upper limit of normal (ULN) OR direct bilirubin \< 1.0 mg/dL (if total bilirubin \> 2.0 mg/dL)
• •ALT \< 5 times ULN
• •Negative pregnancy test
• •Not pregnant or nursing
• •Fertile patients must use effective contraception
• •Families must be able to give consent in English or Spanish
• •No allergy to H1 antihistamines
• •PRIOR CONCURRENT THERAPY:
• •See Disease Characteristics
• •More than 2 weeks since prior chemotherapy, immunotherapy, or radiotherapy and recovered
• •No concurrent anticonvulsants, including valproic acid
• •No concurrent strong inducers or inhibitors of CYP3A4, including grapefruit juice